It has been common for industry advocates and financial analysts to discuss the potential for the NASH/NAFLD drug market in comparison to the statin market, but this overlooks differences in the conditions they treat (NASH vs. hypercholesterolemia), the diagnostics available and the health economic environment.
In this conversation, panelists discuss how complexities in diagnosing the disease and quantifying its nature and severity in individual patient affect patient treatment today and are likely to affect drug uptake. The group provides a thoughtful look at cholesterol drug use could expand more rapidly than NASH drugs will, even if NASH as broader and more far-reaching impact on population health than cholesterol.
TOPICS: Diabetes, EchoSens, ELF, FIB-4, FibroScan, Fibrosis Level 3, MRI-PDFF, NAFLD, NASH, non-invasive liver testing, Perspectum Diagnostics, Hypercholesterolemia, statins, biomarkers, glycemic control, outcomes, pleiotropic effects, metabolic diseases, treatment guidelines, GLP-1s, Fibrosis Level 2, cT1, PRO-C3,
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast